Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVEREST: Everolimus and Epoetin for Sustained Liver Transplant Tolerance
NCT06832189Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2026
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus and epoetin alfa in liver transplantation, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Proportion of subjects free of opportunistic infection attributed to the investigational study regimen, Proportion of subjects free of malignancy attributed to the investigational study regimen and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
everolimusepoetin alfa
03
Conditions
liver transplantation
Beyond the preview
Go deeper on NCT06832189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832189.